ArticlePloS one2026
Predicting elevated transcranial doppler velocity among patients with sickle cell anemia in Uganda: A cross-sectional study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSickle cell anemia (SCA) is an autosomal recessive blood disorder resulting from a specific point mutation in the β-globin gene. Over half a million children are born with sickle cell anemia annually. Transcranial Doppler (TCD) velocity is an accurate predictor of the risk of stroke among children with sickle cell anemia. Unfortunately, TCD screening is not routinely done in developing countries due to limited resources. There is a need to develop a model that predicts elevated TCD velocity, utilizing routinely collected data to guide management of children with sickle cell anemia.
methodsWe conducted a cross-sectional study from 1st July 2024-30th August 2024 among children with SCA attending the Sickle Cell Clinic. We developed a risk-prediction model for elevated TCD (≥ 170 cm/s) using sociodemographic, hematological, and clinical factors. We used the least absolute shrinkage and selection operator (LASSO) penalized regression to select the best subset of predictors of increased TCD velocity. Model performance was assessed by determining the discrimination using the area under the curve and calibration by drawing a calibration plot.
resultsWe enrolled 385 children; the mean age was 10.3 (SD 3.8) years. The prevalence of elevated TCD, defined as ≥170 cm/s was 8.3% (95% CI: 5.8, 11.5; n = 32/385). Using a lambda of 0.008, the final model had 12 predictors. The predictors included neuropathy, red blood cell count, heart rate, age, adherence to hydroxyurea, headache, hematocrit, serum lactate dehydrogenase, gender, malnutrition, blood transfusion, and neutrophils. The model predicted elevated TCD with an AUC of 84.7% (95%CI: 74.7, 90.8).
conclusionWe developed and validated a model to predict elevated TCD among children living with SCA in Uganda. Further exploration is needed to assess whether this model predicts stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.